Human immunodeficiency virus neutralizing antibodies and methods of use thereof
The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
1. A polynucleotide comprising a nucleic acid sequence encoding an anti-HIV antibody or an HIV gp120-derived antigen-binding fragment thereof comprising the CDR1, CDR2, and CDR3 regions of the sequence of SEQ ID NO: 387 and the CDR1, CDR2, and CDR3 regions of the sequence of SEQ ID NO: 558.
2. The polynucleotide of claim 1 , wherein the anti-HIV antibody or an HIV gp120-derived antigen-binding fragment thereof comprises the sequences of SEQ ID NO: 387 and SEQ ID NO: 558.
3. The polynucleotide of claim 1 , wherein the nucleic acid sequence comprises SEQ ID NOs: 993 and 1013.
4. The polynucleotide of claim 1 , wherein the polynucleotide is a DNA, cDNA or RNA molecule.
5. A vector comprising the polynucleotide of claim 1 .
6. The vector of claim 5 , wherein the vector comprises the polynucleotide of claim 2 .
7. The vector of claim 5 , wherein the vector comprises the polynucleotide of claim 3 .
8. The vector of claim 5 is a lentiviral vector.
9. A cell comprising the vector of claim 5 .
10. The cell of claim 9 , wherein the cell comprises the vector of claim 6 .
11. The cell of claim 9 , wherein the cell comprises the vector of claim 7 .
12. A pharmaceutical composition comprising the polynucleotide of claim 1 and optionally a pharmaceutically acceptable carrier.
13. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises the polynucleotide of claim 2 .
14. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises the polynucleotide of claim 3 .
15. A method for treating HIV infection or an HIV-related disease comprising: (a) identifying a patient in need of such treatment, and (b) administering to the patient a therapeutically effective amount of the polynucleotide of claim 1 .
16. The method of claim 15 , wherein the method comprises administering to the patient a therapeutically effective amount of the polynucleotide of claim 2 .
17. The method of claim 15 , wherein the method comprises administering to the patient a therapeutically effective amount of the polynucleotide of claim 3 .